Literature DB >> 25324519

Cardiac troponin I Pro82Ser variant induces diastolic dysfunction, blunts β-adrenergic response, and impairs myofilament cooperativity.

Genaro A Ramirez-Correa1, Aisha H Frazier1, Guangshuo Zhu2, Pingbo Zhang3, Thomas Rappold3, Viola Kooij3, Djahida Bedja4, Greg A Snyder5, Nahyr S Lugo-Fagundo1, Raena Hariharan1, Yuejin Li1, Xiaoxu Shen6, Wei Dong Gao6, Oscar H Cingolani2, Eiki Takimoto2, D Brian Foster2, Anne M Murphy7.   

Abstract

Troponin I (TnI) variant Pro82Ser (cTnIP82S) was initially considered a disease-causing mutation; however, later studies suggested the contrary. We tested the hypothesis of whether a causal link exists between cTnIP82S and cardiac structural and functional remodeling, such as during aging or chronic pressure overload. A cardiac-specific transgenic (Tg) mouse model of cTnIP82S was created to test this hypothesis. During aging, Tg cTnIP82S displayed diastolic dysfunction, characterized by longer isovolumetric relaxation time, and impaired ejection and relaxation time. In young, Tg mice in vivo pressure-volume loops and intact trabecular preparations revealed normal cardiac contractility at baseline. However, upon β-adrenergic stimulation, a blunted contractile reserve and no hastening in left ventricle relaxation were evident in vivo, whereas, in isolated muscles, Ca(2+) transient amplitude isoproterenol dose-response was blunted. In addition, when exposed to chronic pressure overload, Tg mice show exacerbated hypertrophy and decreased contractility compared with age-matched non-Tg littermates. At the molecular level, this mutation significantly impairs myofilament cooperative activation. Importantly, this occurs in the absence of alterations in TnI or myosin-binding protein C phosphorylation. The cTnIP82S variant occurs near a region of interactions with troponin T; therefore, structural changes in this region could explain its meaningful effects on myofilament cooperativity. Our data indicate that cTnIP82S mutation modifies age-dependent diastolic dysfunction and impairs overall contractility after β-adrenergic stimulation or chronic pressure overload. Thus cTnIP82S variant should be regarded as a disease-modifying factor for dysfunction and adverse remodeling with aging and chronic pressure overload.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  cardiac troponin I mutation; diastolic dysfunction; hypertrophy; transgenic mouse

Mesh:

Substances:

Year:  2014        PMID: 25324519      PMCID: PMC4297775          DOI: 10.1152/japplphysiol.00463.2014

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  49 in total

1.  Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.

Authors:  Jens Mogensen; Ross T Murphy; Toru Kubo; Ajay Bahl; James C Moon; Ib C Klausen; Perry M Elliott; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

2.  The backrub motion: how protein backbone shrugs when a sidechain dances.

Authors:  Ian W Davis; W Bryan Arendall; David C Richardson; Jane S Richardson
Journal:  Structure       Date:  2006-02       Impact factor: 5.006

3.  Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly.

Authors:  Hideshi Niimura; Kristen K Patton; William J McKenna; Johann Soults; Barry J Maron; J G Seidman; Christine E Seidman
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

4.  Transgenic mouse model of stunned myocardium.

Authors:  A M Murphy; H Kögler; D Georgakopoulos; J L McDonough; D A Kass; J E Van Eyk; E Marbán
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

5.  Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxation-afterload and force-frequency responses and systolic function.

Authors:  Kenneth C Bilchick; Jennifer G Duncan; Rajashree Ravi; Eiki Takimoto; Hunter C Champion; Wei Dong Gao; Linda B Stull; David A Kass; Anne M Murphy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-08-25       Impact factor: 4.733

6.  Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart.

Authors:  Pingbo Zhang; Jonathan A Kirk; Weihua Ji; Cristobal G dos Remedios; David A Kass; Jennifer E Van Eyk; Anne M Murphy
Journal:  Circulation       Date:  2012-09-12       Impact factor: 29.690

7.  Characterization of the cardiac myosin binding protein-C phosphoproteome in healthy and failing human hearts.

Authors:  Viola Kooij; Ronald J Holewinski; Anne M Murphy; Jennifer E Van Eyk
Journal:  J Mol Cell Cardiol       Date:  2013-04-22       Impact factor: 5.000

8.  An R111C polymorphism in wild turkey cardiac troponin I accompanying the dilated cardiomyopathy-related abnormal splicing variant of cardiac troponin T with potentially compensatory effects.

Authors:  Brandon J Biesiadecki; Kristi L Schneider; Zhi-Bin Yu; Stephen M Chong; Jian-Ping Jin
Journal:  J Biol Chem       Date:  2004-01-20       Impact factor: 5.157

Review 9.  An overview of stress echocardiography in the study of patients with dilated or hypertrophic cardiomyopathy.

Authors:  Wen-Chih Wu; Janak H Bhavsar; George F Aziz; Ara Sadaniantz
Journal:  Echocardiography       Date:  2004-07       Impact factor: 1.724

10.  Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.

Authors:  Bodvaël Fraysse; Florian Weinberger; Sonya C Bardswell; Friederike Cuello; Nicolas Vignier; Birgit Geertz; Jutta Starbatty; Elisabeth Krämer; Catherine Coirault; Thomas Eschenhagen; Jonathan C Kentish; Metin Avkiran; Lucie Carrier
Journal:  J Mol Cell Cardiol       Date:  2012-03-23       Impact factor: 5.000

View more
  6 in total

1.  Heart Failure-Related Hyperphosphorylation in the Cardiac Troponin I C Terminus Has Divergent Effects on Cardiac Function In Vivo.

Authors:  Yuejin Li; Guangshuo Zhu; Nazareno Paolocci; Pingbo Zhang; Cyrus Takahashi; Nazli Okumus; Amir Heravi; Gizem Keceli; Genaro Ramirez-Correa; David A Kass; Anne M Murphy
Journal:  Circ Heart Fail       Date:  2017-09       Impact factor: 8.790

Review 2.  Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility.

Authors:  Yuanhua Cheng; Michael Regnier
Journal:  Arch Biochem Biophys       Date:  2016-02-04       Impact factor: 4.013

3.  Effects of Cardiac Troponin I Mutation P83S on Contractile Properties and the Modulation by PKA-Mediated Phosphorylation.

Authors:  Yuanhua Cheng; Steffen Lindert; Lucas Oxenford; An-Yue Tu; Andrew D McCulloch; Michael Regnier
Journal:  J Phys Chem B       Date:  2016-05-18       Impact factor: 2.991

4.  Mechanical aberrations in hypetrophic cardiomyopathy: emerging concepts.

Authors:  Dimitrios Ntelios; Georgios Tzimagiorgis; Georgios K Efthimiadis; Haralambos Karvounis
Journal:  Front Physiol       Date:  2015-08-19       Impact factor: 4.566

5.  A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation.

Authors:  Christopher N Toepfer; Markus B Sikkel; Valentina Caorsi; Anupama Vydyanath; Iratxe Torre; O'Neal Copeland; Alexander R Lyon; Steven B Marston; Pradeep K Luther; Kenneth T Macleod; Timothy G West; Michael A Ferenczi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

6.  Contribution of Post-translational Phosphorylation to Sarcomere-Linked Cardiomyopathy Phenotypes.

Authors:  Margaret V Westfall
Journal:  Front Physiol       Date:  2016-09-14       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.